TargetBeta
TYK2
tyrosine kinase 2 · also JTK1 · FERM domain containing
13 programs in company-led studies act on TYK2, from 12 companies: 7 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| upadacitinibrule | AbbVie | phase 4 | 6424 running | JAK1, JAK2, JAK3 | ChEMBL |
| ruxolitinibrule | Incyte | phase 4 | 9518 running | JAK1, JAK2, JAK3 | ChEMBL |
| deucravacitinibrule | Bristol-Myers Squibb | phase 4 | 6012 running | – | ChEMBL |
| tofacitinibrule | Pfizer | phase 4 | 943 running | JAK1, JAK2, JAK3 | ChEMBL |
| filgotinib maleaterule | Eisai | phase 4 | 21 running | JAK1, JAK2, JAK3 | ChEMBL |
| D-2570rule | InventisBio | phase 3 | 1311 running | – | the studies' text |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 464 running | JAK1, JAK2, JAK3 | ChEMBL |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 64 running | – | the company's pipeline |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 64 running | – | the company's pipeline |
| FXS5626 | Fosun Pharma | phase 3 | 33 running | JAK1 | the company's pipeline |
| brepocitinibrule | Pfizer | phase 3 | 252 running | JAK1 | NCIt |
| delgocitinibrule | LEO Pharma | phase 3 | 212 running | JAK1, JAK2, JAK3 | ChEMBL |
| TYK2 Inhibitorrule | Usynova Pharmaceuticals | no phase | 11 running | – | NCIt |
Conditions their studies are in
- Psoriasis, 8 programs
- Colitis, Ulcerative, 6 programs
- Arthritis, Psoriatic, 5 programs
- Arthritis, Rheumatoid, 4 programs
- Crohn Disease, 3 programs
- Dermatitis, Atopic, 3 programs
- Lupus Erythematosus, Systemic, 3 programs
- Vitiligo, 3 programs
- Alopecia Areata, 2 programs
- Arthritis, Juvenile, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026upadacitinib · AbbVie · phase 4 · NCT06389136
- Nov 18, 2026deucravacitinib · Bristol-Myers Squibb · phase 4 · NCT05946941
- Nov 21, 2026D-2570 · InventisBio · phase 3 · NCT07715175
- Dec 2026tofacitinib · Pfizer · phase 4 · NCT07843693
- Dec 9, 2026ruxolitinib · Incyte · phase 4 · NCT07049575
- Feb 28, 2027FXS5626 · Fosun Pharma · phase 3 · NCT07552012
- Jun 2027filgotinib · Lakefront Biotherapeutics NV · phase 3 · NCT07554495
- Jun 4, 2027delgocitinib · LEO Pharma · phase 3 · NCT07013201
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.